New Jersey Medical School

Dr. Michael Donovan Joins Cellworks to Oversee Personalized Cancer Therapy Biosimulation in New CLIA-Certified Lab

Retrieved on: 
星期二, 五月 28, 2024

Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.

Key Points: 
  • Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.
  • This new facility signifies a major step forward in Cellworks’ aim to establish a novel transformation in Personalized Therapy Decision Support with an initial focus on delivering personalized therapy predictions for non-small cell lung cancer (NSCLC) patients.
  • The Cellworks Platform coupled with its in silico Computational Biology Model (CBM) utilizes genomic aberrations from a patient’s cancer tumor to reveal how the tumor will respond to therapies.
  • “We have an incredible opportunity to pioneer advancements in Personalized Therapy Biosimulation, starting with important breakthroughs for NSCLC patients.

ENT and Allergy Associates Reinforces Its Commitment to Future Growth by Welcoming Eight New Specialists in 2024

Retrieved on: 
星期四, 五月 16, 2024

Tarrytown, New York, May 16, 2024 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is excited to welcome eight highly-skilled physicians to their team throughout Summer and Fall of 2024.

Key Points: 
  • Tarrytown, New York, May 16, 2024 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is excited to welcome eight highly-skilled physicians to their team throughout Summer and Fall of 2024.
  • Dr. Masood is an avid soccer and table tennis player and enjoys traveling during his leisure time.
  • Lisa Tian, M.D., will join the Upper East Side clinical site in Manhattan on August 1, 2024.
  • He will complete his residency in Otolaryngology at The Icahn School of Medicine at Mount Sinai Hospital in June 2024.

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Retrieved on: 
星期二, 五月 21, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").
  • “Through our initiatives to raise awareness and increase collaboration in the field of spinal cord injury, we have encountered an enthusiastic response to this conference from a diverse and innovative group of companies and other stakeholders.
  • “We are excited to add a BCI-focused clinical session this year with the inclusion of Neuralink and several additional corporate presenters.
  • , Chief Medical Officer, Kessler Foundation, Professor of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School

Phoenix Children's Names New Chief of Neurosurgery

Retrieved on: 
星期三, 四月 24, 2024

PHOENIX, April 24, 2024 /PRNewswire/ -- Phoenix Children's, one of the nation's fastest-growing pediatric health systems, today announced the hire of accomplished surgeon-scientist Jason Scott Hauptman, MD, PhD, as division chief of neurosurgery, part of Barrow Neurological Institute at Phoenix Children's. His appointment is part of a broader effort to hire top clinical and research leadership in high-demand specialty areas as Phoenix Children's solidifies its position as the premier pediatric health system in the Southwest.

Key Points: 
  • "Patient families will benefit from Dr. Hauptman's epilepsy surgery expertise, and our health system will benefit from his impressive track record in medical education, mentorship, research and academia," said Daniel Ostlie, MD, surgeon in chief at Phoenix Children's.
  • As division chief of neurosurgery at Phoenix Children's , Dr. Hauptman will provide strategic direction and administrative leadership while also collaborating with multidisciplinary teams to provide top-quality clinical care for children with neurological conditions.
  • He will also hold academic appointments with Mayo Clinic Arizona, Creighton University School of Medicine and the University of Arizona College of Medicine — Phoenix.
  • Phoenix Children's is consistently recognized as one of U.S. News & World Report's " Best Children's Hospitals " for neurology and neurosurgery.

One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors

Retrieved on: 
星期三, 三月 27, 2024

to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.

Key Points: 
  • to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.
  • Our proprietary discovery engine has identified its first promising targets, and we are preparing to start drug development activities in 2025.
  • Bolstering our Board with such seasoned leaders will be a key factor to success.”
    Dr. Scott Braunstein brings over 30 years of knowledge and experience gained in the biotechnology, pharmaceutical, and biotech portfolio management industries.
  • Dr. Braunstein is currently on the board at Trevena and Caribou Biosciences.

RWJBarnabas Health and Rutgers Health to Showcase Breakthrough Cardiology Data at the American College of Cardiology Scientific Session & Expo

Retrieved on: 
星期一, 三月 25, 2024

WEST ORANGE, N.J., March 25, 2024 /PRNewswire/ -- Physician-scientists from RWJBarnabas Health and Rutgers Health will present an extensive portfolio of innovative cardiovascular data from their clinical research program at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Atlanta, Georgia on April 6 to 8, 2024. A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.

Key Points: 
  • A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.
  • RWJBarnabas Health cardiac centers of excellence are nationally recognized for patient care and superior outcomes, including being named as one of Becker's top 100 Great Heart Programs in the country and recognized by American College of Cardiology as a Proven Quality Program.
  • Prior studies suggest that distinct patient subgroups with aortic stenosis may experience left ventricular systolic and diastolic dysfunction before the development of severe AS.
  • The study included patients who had received an angiogram done within 14 days of the CMR.

Knock Out Opioid Abuse Day Learning Series Returns in 2024

Retrieved on: 
星期三, 一月 24, 2024

Millburn, NJ, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Partnership for a Drug-Free New Jersey (PDFNJ), the Office of the New Jersey Coordinator for Addiction Responses and Enforcement Strategies (NJ CARES) and the Opioid Education Foundation of America (OEFA) have renewed their partnership in 2024 and will once again host the Knock Out Opioid Abuse Day Learning Series.

Key Points: 
  • Millburn, NJ, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Partnership for a Drug-Free New Jersey (PDFNJ), the Office of the New Jersey Coordinator for Addiction Responses and Enforcement Strategies (NJ CARES) and the Opioid Education Foundation of America (OEFA) have renewed their partnership in 2024 and will once again host the Knock Out Opioid Abuse Day Learning Series.
  • Over the course of 11 webinars from January to December 2024, the series will offer the public more insight and information into the multi-faceted components of the opioid epidemic in New Jersey and around the nation.
  • The series is a branch of PDFNJ’s Knock Out Opioid Abuse Day statewide initiative, which has been held annually on October 6 since 2016 to educate residents and prescribers on the risks of prescription opioids and to raise awareness of the opioid crisis throughout the state.
  • To learn more about Knock Out Opioid Abuse Day and for a schedule of webinars, please visit knockoutday.drugfreenj.org .

ENT and Allergy Associates, LLP Strengthens Commitment to Excellence Welcomes Otolaryngologist Guy Talmor, M.D. to West Nyack, NY Office

Retrieved on: 
星期四, 十二月 21, 2023

With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.

Key Points: 
  • With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.
  • Dr. Talmor earned his Bachelor of Science degree in physiology and neuroscience from the University of California at San Diego.
  • He went on to receive his medical degree from the prestigious Keck School of Medicine of University of Southern California, graduating summa cum laude.
  • Dr. Talmor will complete his ENT residency at Rutgers New Jersey Medical School in June 2024.

NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System

Retrieved on: 
星期一, 十二月 11, 2023

EDEN PRAIRIE, Minn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance to market its OneRF™ Ablation System for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures.

Key Points: 
  • This may also reduce hospital stays, number of surgeries, and adverse events, while offering significant benefits from a clinical perspective.
  • The addition of temperature control at the point of ablation also may enhance patient safety.
  • The OneRF Ablation System is the Company’s first device with a therapeutic indication and its third FDA 510(k)-cleared device.
  • NeuroOne estimates the current brain ablation market to be at least $100M worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs.

ENT and Allergy Associates, LLP Continues to Add Talented Physicians Welcomes Otolaryngologist Monica Christine Azmy, M.D. to its Old Bridge, NJ Office

Retrieved on: 
星期一, 十一月 13, 2023

To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.

Key Points: 
  • To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.
  • This continues with Monica Christine Azmy, M.D., who is the latest recruit to join the group's 240+ board-certified physicians.
  • Dr. Azmy will begin seeing patients at ENTA’s Old Bridge, NJ office effective October 1, 2024.
  • To learn more about ENTA, find a local office or book an appointment, visit www.entandallergy.com or call 1-855-ENTA-DOC.